Literature DB >> 12368693

Adverse outcomes in primary hemophagocytic lymphohistiocytosis.

Lillian Sung1, Susan M King, Manuel Carcao, Monika Trebo, Sheila S Weitzman.   

Abstract

PURPOSE: Hemophagocytic lymphohistiocytosis (HLH) is a rare condition characterized by abnormal proliferation of macrophages. Although the mortality rate in children diagnosed with primary HLH is high, little has been described about the nature of adverse events. This review evaluates unfavorable events in children with primary HLH to suggest methods of improving outcomes.
METHODS: Charts of patients who met diagnostic criteria for primary HLH at the Hospital for Sick Children between January 1985 and June 2000 were retrospectively reviewed. The primary outcome measure was an adverse event, defined as death, the subsequent diagnosis of malignancy, or developmental delay.
RESULTS: Twenty children were diagnosed with primary HLH. The median age at diagnosis was 6.5 months (range 1-78 months). Nineteen children received chemotherapy and two underwent matched sibling donor bone marrow transplantation. Of the 20 children, 12 (60%) died. These deaths were attributed to progressive HLH in 4 cases and invasive infection in 8 cases. These infections consisted of disseminated cytomegalovirus infection (n = 1), sepsis (n = 1), and invasive fungal infections (n = 6). Eight children survived. Two were subsequently diagnosed with malignancy. Two others were found to have significant developmental delay.
CONCLUSIONS: The overall mortality rate was 60% in our series of 20 children with primary HLH; 50% of deaths were directly attributable to invasive fungal infection. Developmental delay and the diagnosis of malignancy are important events in this cohort.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12368693     DOI: 10.1097/00043426-200210000-00011

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  11 in total

Review 1.  Lymphoma presenting as secondary HLH: a review with a tale of two cases.

Authors:  Abhimanyu Ghose; Mahender Yellu; Trisha Wise-Draper; Divya Sharma; Julianne Qualtieri; Tahir Latif; Stephen Medlin
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2014-06-21

Review 2.  Pathogenesis of macrophage activation syndrome and potential for cytokine- directed therapies.

Authors:  Grant S Schulert; Alexei A Grom
Journal:  Annu Rev Med       Date:  2014-11-05       Impact factor: 13.739

3.  Hematopoietic cell transplantation for treatment of primary immune deficiencies.

Authors:  Lauri Burroughs; Ann Woolfrey
Journal:  Cell Ther Transplant       Date:  2010-08-31

Review 4.  Cytokine storm and targeted therapy in hemophagocytic lymphohistiocytosis.

Authors:  Han-Qi Zhang; Si-Wei Yang; Yi-Cheng Fu; Ming-Cong Chen; Cheng-Hao Yang; Ming-Hua Yang; Xiao-Dan Liu; Qing-Nan He; Hua Jiang; Ming-Yi Zhao
Journal:  Immunol Res       Date:  2022-07-11       Impact factor: 4.505

Review 5.  Macrophage activation syndrome and cytokine-directed therapies.

Authors:  Grant S Schulert; Alexei A Grom
Journal:  Best Pract Res Clin Rheumatol       Date:  2014-04       Impact factor: 4.098

Review 6.  Recent advances in the diagnosis and treatment of hemophagocytic lymphohistiocytosis.

Authors:  Sebastian Fn Bode; Kai Lehmberg; Andrea Maul-Pavicic; Thomas Vraetz; Gritta Janka; Udo Zur Stadt; Stephan Ehl
Journal:  Arthritis Res Ther       Date:  2012-06-08       Impact factor: 5.156

7.  Hyperferritinemia in the critically ill child with secondary hemophagocytic lymphohistiocytosis/sepsis/multiple organ dysfunction syndrome/macrophage activation syndrome: what is the treatment?

Authors:  Demet Demirkol; Dincer Yildizdas; Benan Bayrakci; Bulent Karapinar; Tanil Kendirli; Tolga F Koroglu; Oguz Dursun; Nilgün Erkek; Hakan Gedik; Agop Citak; Selman Kesici; Metin Karabocuoglu; Joseph A Carcillo
Journal:  Crit Care       Date:  2012-12-12       Impact factor: 9.097

8.  Differentiation between incomplete Kawasaki disease and secondary hemophagocytic lymphohistiocytosis following Kawasaki disease using N-terminal pro-brain natriuretic peptide.

Authors:  Jung Eun Choi; Yujin Kwak; Jung Won Huh; Eun-Sun Yoo; Kyung-Ha Ryu; Sejung Sohn; Young Mi Hong
Journal:  Korean J Pediatr       Date:  2018-05-28

Review 9.  Cell Versus Cytokine - Directed Therapies for Hemophagocytic Lymphohistiocytosis (HLH) in Inborn Errors of Immunity.

Authors:  Oliver Wegehaupt; Katharina Wustrau; Kai Lehmberg; Stephan Ehl
Journal:  Front Immunol       Date:  2020-05-08       Impact factor: 7.561

Review 10.  Hemophagocytic lymphohistiocytosis in an adult kidney transplant recipient successfully treated by plasmapheresis: A case report and review of the literature.

Authors:  Christian Nusshag; Christian Morath; Martin Zeier; Markus A Weigand; Uta Merle; Thorsten Brenner
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.